Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
NCT ID: NCT01469338
Last Updated: 2014-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
9 participants
INTERVENTIONAL
2012-07-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the impact of octreotide in reducing the incidence of grade 2 or greater diarrhea in men receiving cabazitaxel plus prednisone for castration-resistant prostate cancer (CRPC) after docetaxel therapy.
SECONDARY OBJECTIVES:
I. Overall survival (OS).
II. Progression-free survival (PFS) (defined as the time between treatment start and the first date of progression as measured by objective tumor progression using the Response Evaluation Criteria In Solid Tumors (RECIST), pain progression or death).
III. Prostate-specific antigen (PSA) response rate.
IV. Objective response rate.
V. Pain response.
VI. Toxicity.
OUTLINE:
Patients receive cabazitaxel as intravenous (IV) infusion over 1 hour on day 1, prednisone by mouth (PO) every day (QD), and octreotide pamoate given as intramuscular (IM) injection on day 1. Patients also receive octreotide acetate as a subcutaneous (SC) injection three times a day (TID) on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1 month, every 3 months until disease progression, and then every 6 months thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supportive care (management of therapy complications)
Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
cabazitaxel
Given IV
prednisone
Given PO
octreotide pamoate
Given IM
questionnaire administration
Ancillary studies
octreotide acetate
Given SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cabazitaxel
Given IV
prednisone
Given PO
octreotide pamoate
Given IM
questionnaire administration
Ancillary studies
octreotide acetate
Given SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease on computed tomography (CT) or evaluable disease with an elevated PSA
* Documented progression on (a) at least one prior hormone treatment, which must have incorporated luteinizing hormone-releasing hormone (LHRH) agonist therapy AND (b) at least one chemotherapy regimen, which must have included docetaxel; progression may be demonstrated by radiologic criteria or by PSA only if accompanied by new or worsening symptoms (pain progression)
* Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
* Absolute neutrophil count (ANC) more than or equal to 1500/ul
* Hemoglobin more than or equal to 8.0 g/dL
* Platelet count more than or equal to 100,000/ul
* Serum creatinine less than or equal to 1.5x the upper limit of normal (ULN)
* Bilirubin less than or equal to ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 1.5x ULN
* Must be recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapy
* Patients or their legal representatives must be able to read, understand, and provide informed consent
* Men of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafter
* Palliative radiation for metastatic disease is allowed if less or equal to 40% of the total bone marrow was irradiated; 28 days must have elapsed since completion of radiation therapy (RT) with bone marrow recovery; soft tissue disease irradiated in the prior 2 months may not be designated as measurable disease
* Concomitant bisphosphonate use is permitted if the dose had been stable for 12 weeks prior to enrollment
Exclusion Criteria
* Major surgery in the prior 4 weeks
* Prior treatment with cabazitaxel
* Patients with known hypersensitivity to cabazitaxel, other drugs formulated with polysorbate 80 or octreotide
* Inability to tolerate oral prednisone
* Grade 2 or greater diarrhea in the prior 2 weeks
* Grade 2 or greater neuropathy or stomatitis
* Presence of an active uncontrolled infection or fever greater or equal to 38.5 degrees
* Presence of parenchymal brain metastases; patients with neurological symptoms must have a CT or magnetic resonance imaging (MRI) of the brain showing no metastases within 60 days of enrollment
* Prior malignancy within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder or other stage I or stage II cancer in complete remission for at least 12 months
* History of unstable or newly diagnosed angina pectoris, documented history of current serious arrhythmia or congestive heart failure (CHF) or recent myocardial infarction (MI)within 6 months of enrollment
* Known human immunodeficiency virus (HIV) or hepatitis infection
* Life expectancy less than 3 months
* Presence of any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with interpretation of the results
* Lack of ability/willingness to give informed consent
* Lack of ability/willingness to receive octreotide injection
* Anticipated non-availability for study visits/procedures
* Patients with uncontrolled diabetes, defined as a HbA1c greater than 7% or greater or equal to 8% despite therapy, or a fasting plasma glucose more than 2x ULN; at the investigator's discretion, non-eligible patients can be re-screened after adequate medical therapy has been instituted
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sanofi
INDUSTRY
University of Southern California
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacek Pinski
Role: PRINCIPAL_INVESTIGATOR
University of Southern California
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-03266
Identifier Type: REGISTRY
Identifier Source: secondary_id
4P-11-3
Identifier Type: -
Identifier Source: org_study_id